CoChat

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics

Boden, William E, Bhatt, Deepak L, Toth, Peter P, Ray, Kausik K, Chapman, M John, Lüscher, Thomas F · 2020 · European Heart Journal
Cited by 72

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a major contributor to residual atherosclerotic cardiovascular disease (ASCVD) risk, particularly among patients with type 2 diabetes mellitus, metabolic syndrome, and obesity whose distinctive lipid phenotype cannot be optimally treated with LDL-C reduction therapy alone; (ii) describe the findings and clinical implications of the landmark REDUCE-IT trial in which ethyl eicosapentaenoic acid significantly improved ASCVD outcomes. While many genetic studies have shown that elevated TG are an independent causal factor for ASCVD, prior placebo-controlled trials using niacin, fibrates, omega-3 fatty acids, and dietary supplement fish oil preparations have failed to demonstrate significant CV event reduction when added to statin therapy. In contrast, the REDUCE-IT trial in 8179 participants showed convincingly that the administration of 4 g daily of icosapent ethyl (an ethyl ester of eicosapentaenoic acid) in patients at high risk for ASCVD with increased levels of baseline TG [median value, 2.44 mmol/L (216.0 mg/dL)] but well-controlled LDL-C [median value, 1.94 mmol/L (75.0 mg/dL)] reduced significantly incident events across both the trial primary endpoint and multiple prespecified secondary endpoints, including cardiovascular death, as well as both subsequent and total primary endpoint and key secondary endpoint events. Icosapent ethyl unequivocally contributed to ASCVD event reduction over and above statin therapy. The REDUCE-IT trial results should alter our approach to managing a growing population of hypertriglyceridaemic patients whose lipid phenotype requires more intensive treatment beyond LDL-C lowering alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehz778

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC BY-NC · PubMed Central
Figure 1 Prespecified hierarchical testing of a variety of individual and composite ischaemic endpoints, showing significant reductions in endpoints such as cardiovascular death (with permission from Bhatt et al.40).
Figure 1 Prespecified hierarchical testing of a variety of individual and composite ischaemic endpoints, showing significant reductions in endpoints such as cardiovascular death (with permission from Bhatt et al.40).CC BY-NC · PubMed Central
Figure 2 Reduction in cardiovascular death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina in time to first event and total event analyses in REDUCE-IT (with permission from Bhatt et al.43).
Figure 2 Reduction in cardiovascular death, myocardial infarction, stroke, coronary revascularization, and hospitalization for unstable angina in time to first event and total event analyses in REDUCE-IT (with permission from Bhatt et al.43).CC BY-NC · PubMed Central
Figure 3 Reduction in cardiovascular death, myocardial infarction, and stroke in time to first event and total event analyses in REDUCE-IT (with permission from Bhatt et al.43).
Figure 3 Reduction in cardiovascular death, myocardial infarction, and stroke in time to first event and total event analyses in REDUCE-IT (with permission from Bhatt et al.43).CC BY-NC · PubMed Central
Figure 4 Reduction in first and subsequent ischaemic events in REDUCE-IT (with permission from Bhatt et al.43).
Figure 4 Reduction in first and subsequent ischaemic events in REDUCE-IT (with permission from Bhatt et al.43).CC BY-NC · PubMed Central
Figure 5 Number of ischaemic events prevented by icosapent ethyl for every 1000 patients treated for 5 years in REDUCE-IT (with permission from Bhatt et al.43).
Figure 5 Number of ischaemic events prevented by icosapent ethyl for every 1000 patients treated for 5 years in REDUCE-IT (with permission from Bhatt et al.43).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 15

  1. Hong, 2017, How low to go with glucose, cholesterol, and blood pressure in primary prevention of CVD, J Am Coll Cardiol, 70, 2171, 10.1016/j.jacc.2017.09.001 · DOI · Paper page
  2. Rosinger, 2017, Trends in total cholesterol, triglycerides, and low-density lipoprotein in US adults, 1999-2014, JAMA Cardiol, 2, 339, 10.1001/jamacardio.2016.4396 · DOI · Paper page
  3. Amber, 2013, Dyslipidaemia and atherosclerotic vascular disease: DYSIS results in the UK, Br J Cardiol, 20, S9
  4. Musunuru, 2016, Surprises from genetic analyses of lipid risk factors for atherosclerosis, Circ Res, 118, 579, 10.1161/CIRCRESAHA.115.306398 · DOI · Paper page
  5. Chapman, 2011, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management, Eur Heart J, 32, 1345, 10.1093/eurheartj/ehr112 · DOI · Paper page
  6. Robinson, 2012, Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials, Am J Cardiol, 110, 1468, 10.1016/j.amjcard.2012.07.007 · DOI
  7. Kohli, 2009, Resolvins and protectins: mediating solutions to inflammation, Br J Pharmacol, 158, 960, 10.1111/j.1476-5381.2009.00290.x · DOI · Paper page
  8. Alexander, 2017, A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk, Mayo Clin Proc, 92, 15, 10.1016/j.mayocp.2016.10.018 · DOI · Paper page
  9. Rizos, 2012, Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis, JAMA, 308, 1024, 10.1001/2012.jama.11374 · DOI · Paper page
  10. Bucher, 2002, N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials, Am J Med, 112, 298, 10.1016/S0002-9343(01)01114-7 · DOI · Paper page
  11. Kwak, 2012, Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials, Arch Intern Med, 172, 686, 10.1001/archinternmed.2012.262 · DOI
  12. Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
  13. Nosaka, 2017, Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study, Int J Cardiol, 228, 173, 10.1016/j.ijcard.2016.11.105 · DOI · Paper page
  14. Aung, 2018, Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals, JAMA Cardiol, 3, 225, 10.1001/jamacardio.2017.5205 · DOI · Paper page
  15. Orringer, 2019, National Lipid Association position on the use of icosapent ethyl in high and very high risk patients, Clin Lipid Update, 2019

Cited by

See all 72

Metadata

Authors
Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F.
Affiliations
  • VA New England Healthcare System, Boston University School of Medicine , 150 S. Huntington Avenue, Boston, MA 02130, USA
  • Brigham and Women’s Hospital Heart & Vascular Center , Harvard Medical School, Boston, MA, USA
  • CGH Medical Center , Sterling, IL, USA
  • Imperial Centre for Cardiovascular Disease Prevention, School of Public Health , Imperial College London, London, UK
  • Sorbonne University, Pitie-Salpetriere University Hospital , Paris, France
  • University Heart Center, University Hospital , Zurich, Switzerland
Venue
European Heart Journal
Published
2019-12-23
Volume
41
Issue
24
Pages
2304-2312
ISSN
  • 0195-668X
  • 1522-9645
Cited by
72
References
41
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. https://app.cochat.ai/papers/10.1093/eurheartj/ehz778
The paper
Boden, W. E., Bhatt, D. L., Toth, P. P., Ray, K. K., Chapman, M. J., & Lüscher, T. F. (2020). Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. European Heart Journal. https://doi.org/10.1093/eurheartj/ehz778

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.